title: Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment.
abstract: OBJECTIVE
  To assess the validity of contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment by using histology as the reference standard.
  
  
  METHODS
  H22 hepatoma-bearing mice were treated with thalidomide or placebo by intraperitoneal injection. Contrast-enhanced ultrasound was performed on day 8 after bolus injection of SonoVue. Three different parametric perfusion images were calculated based on the following parameters: area under the curve (AUC), maximum intensity (IMAX) and perfusion index (PI). A score from 1 to 5 (1 = low, 5 = excellent) was used for analysis of parametric perfusion images by two independent readers. Immunohistochemical analysis was performed for evaluation of microvascular density (MVD).
  
  
  RESULTS
  Treatment with thalidomide resulted in a significant decrease in perfusion scores assigned to AUC, IMAX and PI parametric images as compared with control tumors (P < 0.001). Immunohistochemistry showed significant decreases of MVD in treated tumors as compared with control tumors (P = 0.002). MVD was positively correlated with the perfusion scores assigned to AUC parametric images (r = 0.568, P = 0.009), IMAX parametric images (r = 0.614, P = 0.004) and PI parametric images (r = 0.636, P = 0.003).
  
  
  CONCLUSIONS
  Contrast-enhanced ultrasonic parametric perfusion imaging provides a noninvasive tool to directly visualize tumor perfusion changes after antiangiogenic tumor treatment.
authors.affiliation: Department of Ultrasound, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR China.
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Zhou
authors.forename: Wei
authors.initials: W
authors.lastname: Zheng
authors.forename: Long-Hui
authors.initials: LH
authors.lastname: Cao
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.forename: Rong-Zhen
authors.initials: RZ
authors.lastname: Luo
authors.forename: Feng
authors.initials: F
authors.lastname: Han
authors.forename: Pei-Hong
authors.initials: PH
authors.lastname: Wu
authors.forename: An-Hua
authors.initials: AH
authors.lastname: Li
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D019540:Area Under Curve; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D003287:Contrast Media; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008833:Microcirculation / Q000187:drug effects; D010743:Phospholipids; D013459:Sulfur Hexafluoride; D013792:Thalidomide / Q000494:pharmacology*; D014463:Ultrasonography
chemical_list: D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D010743:Phospholipids; C420843:contrast agent BR1; D013792:Thalidomide; D013459:Sulfur Hexafluoride